公开(公告)号：US20240140959A1

公开(公告)日：2024-05-02

申请号：US18497296

申请日：2023-10-30

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James Anthony NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20230212139A1

公开(公告)日：2023-07-06

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210107889A1

公开(公告)日：2021-04-15

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20220411435A1

公开(公告)日：2022-12-29

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210130365A1

公开(公告)日：2021-05-06

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.